Vaxcyte, Inc. (PCVX)

Over the past six months, Vaxcyte's stock price has been influenced by several events. In November 2025, the company reported third-quarter financial results and provided final data from the VAX-24 infant Phase 2 dose-finding study. In December 2025, vaccine stocks experienced a slide after an FDA official linked COVID vaccines and heart conditions. In January 2026, Vaxcyte dosed the first participants in its OPUS-2 Phase 3 trial for VAX-31 and completed enrollment in the VAX-31 infant Phase 2 dose-finding study, with Needham & Company LLC increasing their target price. In February 2026, Vaxcyte reported fourth-quarter and full-year financial results, advanced its VAX-31 adult Phase 3 clinical program, and completed an equity offering. BTIG Research and Guggenheim increased or reaffirmed their target prices. In March 2026, positive VAX-31 Phase 1/2 adult data was published, and Vaxcyte completed enrollment in its OPUS-1 and OPUS-2 Phase 3 trials for VAX-31. In April 2026, Wall Street Zen downgraded Vaxcyte's stock rating, while other analysts maintained a "Moderate Buy" consensus, and Vaxcyte reported quarterly EPS that missed estimates.

As a clinical-stage vaccine innovation company, Vaxcyte's products are currently in clinical development and not yet commercialized. Therefore, traditional demand seasonality is not applicable at this time.

Vaxcyte, Inc. is a clinical-stage vaccine innovation company focused on engineering high-fidelity vaccines against serious bacterial infectious diseases. The company operates in the Healthcare sector and Biotechnology industry, leveraging its XpressCF cell-free protein synthesis platform to develop vaccine candidates. Key product pipeline candidates include VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) candidate in Phase 3 adult and Phase 2 infant clinical programs; VAX-24, a 24-valent PCV candidate in a Phase 2 infant study; VAX-XL, a third-generation PCV candidate in early-stage development; VAX-A1, a novel conjugate vaccine candidate against Group A Streptococcus infections; VAX-GI, a preclinical vaccine candidate against Shigella infections; and VAX-PG, a novel protein vaccine candidate targeting the pathogen responsible for periodontal disease.

Vaxcyte, Inc. is headquartered in San Carlos, California, United States. The company has initiated the buildout of a high-volume, custom fill-finish line in North Carolina. Vaxcyte has also completed the construction of a dedicated, large-scale manufacturing facility in collaboration with Lonza to support potential global commercial manufacturing of its PCV candidates.

Vaxcyte's brand reputation is reflected through analyst sentiment and industry news. The company generally holds a "Moderate Buy" consensus rating from analysts, but a recent downgrade to "strong sell" indicates mixed sentiment. Events affecting the broader vaccine industry could indirectly influence investor perception of Vaxcyte.

Institutional investors hold the majority of Vaxcyte's shares, with 298 institutional owners and shareholders holding a total of 146,557,148 shares. Major institutional owners include Fmr Llc, Janus Henderson Group Plc, Vanguard Group Inc, T. Rowe Price Investment Management, Inc., RA Capital Management, L.P., BlackRock, Inc., Wellington Management Group Llp, State Street Corp, Paradigm Biocapital Advisors LP and Deep Track Capital, LP. Individual shareholders represent a small fraction of ownership, with Tpg Group Holdings Sbs Advisors Inc noted as a large individual shareholder.